Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
41.59 USD -0.60% Intraday chart for Ionis Pharmaceuticals, Inc. +2.24% -17.79%
Sales 2024 * 622M 49.82B Sales 2025 * 773M 61.88B Capitalization 6.07B 486B
Net income 2024 * -573M -45.87B Net income 2025 * -496M -39.71B EV / Sales 2024 * 9.57 x
Net cash position 2024 * 111M 8.88B Net Debt 2025 * 218M 17.47B EV / Sales 2025 * 8.13 x
P/E ratio 2024 *
-10.5 x
P/E ratio 2025 *
-12.4 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.60%
1 week+2.24%
Current month-4.06%
1 month-6.87%
3 months-19.23%
6 months-5.58%
Current year-17.79%
More quotes
1 week
40.58
Extreme 40.575
42.73
1 month
40.39
Extreme 40.385
44.08
Current year
40.39
Extreme 40.385
54.44
1 year
34.32
Extreme 34.32
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
75.14
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 30/06/12
Founder 62 09/01/89
Director of Finance/CFO 62 30/04/00
Members of the board TitleAgeSince
Chairman 72 02/02/14
Founder 62 09/01/89
Director/Board Member 70 09/06/19
More insiders
Date Price Change Volume
26/04/24 41.59 -0.60% 556,093
25/04/24 41.84 -1.44% 1,142,810
24/04/24 42.45 +1.46% 731,441
23/04/24 41.84 +1.87% 631,237
22/04/24 41.07 +0.96% 705,230

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
41.59 USD
Average target price
58.13 USD
Spread / Average Target
+39.77%
Consensus